Recently reported by Managed Healthcare Executives, the healthcare industry is abuzz with predictions about the future of the Affordable Care Act (ACA). As stakeholders anxiously await the impact of a Trump administration agenda, there is at least one safe bet that all can make: value-based care is here to stay.
As such, providers and payers must remain undeterred in their efforts to deploy the best infrastructures and strategies for future positioning. Forward-looking organizations recognize that arming physicians with evidence-based clinical decision support tools and analytics at the point of care is critical to this equation.
Treatment guidelines combined with population data-based predictive modeling and physiological duration data to set realistic recovery expectations with patients aligns with Trump’s strong advocacy of greater consumer engagement to drive down costs. Any new platform is expected to resolutely emphasize consumer choice, cost containment, clinical performance and value.
Equipping physicians with evidence-based guidelines and other decision support tools at the point of care will prepare organizations for any of these platform elements, but also for value-based care models, which the industry at large increasingly acknowledges and embraces.
Trump administration: same goals, new strategy
Current movements on the national stage suggest that a full repeal of current legislation is unlikely. The reality is that some aspects of ACA and value-based care are effective, and it is more probable that efforts will prioritize elimination of elements that are unpopular with voters and do not align with the Trump platform.
For instance, a less-regulated approach to alternative payment models is predicted as is increased oversight of payment reform decisions made by CMS. In addition, Trump’s previous policy statements point to a preference for bundled payment expansion and Medicaid reform in place of Medicare shared savings programs and accountable care organizations.
One key piece of legislation—the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)—was strongly bipartisan and is expected to unfold as planned. The January 1 enactment of this law will considerably raise the stakes for value-based care, shifting the philosophical focus for participation from incentives to penalties.
Follow the link below to read this article in its entirety:
Managed Healthcare Executive – The healthcare industry trend that won’t change with Trump